Promising drug targets rare cancer that Won't stop growing

NCT ID NCT07104331

Recruiting now Disease control Sponsor: Sarcoma Alliance for Research through Collaboration Source: ClinicalTrials.gov ↗

First seen Feb 20, 2026 · Last updated May 16, 2026 · Updated 7 times

Summary

This study tests a drug called nab-sirolimus in 41 people with a rare cancer of the blood vessels called epithelioid hemangioendothelioma (EHE) that is getting worse or causing symptoms. The drug is given through a vein twice every three weeks. The main goal is to see if it shrinks tumors or stops them from growing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Brigham and Women's Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Sloan Kettering Institute for Cancer Research
NOT_YET_RECRUITING

New York, New York, 10065, United States
Stanford University
NOT_YET_RECRUITING

Stanford, California, 94305, United States
University of Colorado
NOT_YET_RECRUITING

Aurora, Colorado, 80203, United States
Washington University St. Louis
NOT_YET_RECRUITING

St Louis, Missouri, 63130, United States

Conditions

Explore the condition pages connected to this study.

EPITHELIOID HEMANGIOENDOTHELIOMA (EHE)